Oxford BioDynamics Launches EpiSwitch CiRT Blood Test for the Treatment of Cancer in the UK
Shots:
- The company launched CiRT clinical blood test which predicts a patient's likely response to ICI therapies. The test will be available to private healthcare providers in the UK as an LDT
- Across several ICIs from multiple pharmaceutical companies & 15+ oncological indications, the robust EpiSwitch qPCR blood test has demonstrated best-in-class performance with high sensitivity (93%), specificity (82%), accuracy (85%) & NPV of 93%
- CiRT provides a physician with immediate, personalized guidance on expected efficacy, allowing them to make a more informed decision to begin or continue treatment. This expansion to the UK was based on early uptake of EpiSwitch CiRT by early adopters in the US, first launched as an LDT in Feb 2022
Ref: Bussinesswire | Image: Oxford BioDynamics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
